No Data
Major MSCI adjustment! Brokerage stocks are most favored, 20 companies are being removed.
On November 7th, Beijing time, the international index compiler MSCI announced the results of the November stock index review. Among them, 4 Chinese stocks were newly included in the MSCI China Index, while 20 individual stocks were removed. All changes will take effect after the market closes on November 25, 2024.
Pacific Shuanglin Bio-Pharmacy (000403): Stable performance growth, looking forward to long-term empowerment space from major shareholder.
Company Update: The company released the third quarter report of 2024, achieving revenue of 1.89 billion yuan in the first three quarters of 2024, a year-on-year growth of 37.5%, achieving a net income attributable to the parent of 0.54 billion yuan, a year-on-year growth of 66.4%; 24.
pacific shuanglin bio-pharmacy (000403) 2024 Third Quarter Report Review: Outstanding performance with continued improvement in profitability.
Event: On October 27th, the company released the third quarter report of 2024. From 2024 Q1 to Q3, the company achieved revenue of 1.89 billion yuan, an increase of 37.49% year-on-year; net income attributable to the parent company was 0.543 billion yuan, an increase of 66.38% year-on-year.
Express News | pacific shuanglin bio-pharmacy: Two subsidiaries obtained single-use plasma license.
Pailin Biotech: Report for the third quarter of 2024
Pacific Shuanglin Bio-Pharmacy (000403.SZ): The company has achieved exports to countries such as Brazil and Pakistan.
On October 18th, Grasp Gene Corporation pacific shuanglin bio-pharmacy (000403.SZ) stated on the investor interactive platform that the company has been actively promoting its overseas market layout, exporting to countries such as Brazil and Pakistan, and will also actively seek other development opportunities in the future.
